BioLineRx heads into its third-quarter report with a stock that has lost more than 60% of its value since the last update, even as management describes its lead brain cancer program as moving faster and attracting more interest than before. That gap between scientific momentum and market punishment is the story. The release before the open on November 23 will be judged less on the income statement than on whether the balance sheet can carry Glix-1 to its first meaningful data readout, now guided for the first half of 2027.
The Street is looking for a loss of $0.38 per share on revenue of roughly $360,000. That loss would be about half the $0.77 deficit posted last quarter but wider than the $0.22 loss from a year ago, a 72.7% deterioration on a year-over-year basis. Revenue is expected to fall nearly 16% from the $0.4 million booked in the same quarter of 2025. Management has not issued formal financial guidance, so the most useful yardstick is its own repeated statement that cash should last into the first half of 2027. That phrase has not budged across three consecutive calls, even as cash slid from $20.9 million at year-end to $13.1 million at the end of June.
That erosion is the first test. Last quarter's $3.75 million offering should show up in the September cash balance, and the key figure is whether quarterly burn continues at the roughly $4 million pace seen in the second quarter. If management reaffirms the runway without new caveats, the dilution will look like a bridge rather than the first in a series. Any softening of that timeline, or hints that another raise is needed before Phase 1 data, would likely overshadow everything else in the release.
Revenue matters mainly as a read on Afexta, the partnered product that generates BioLineRx's royalty stream. In the first quarter, management framed Afexta sales as entering an upward curve, only to see them fall to $1.6 million in the second quarter from $2.5 million, with royalties sliding from $0.5 million to $0.3 million. Consensus near $360,000 implies a modest rebound at best. A figure meaningfully above that would suggest the second-quarter dip was noise; another decline would confirm that the commercial narrative has stalled and leave the company even more dependent on capital markets.
On the clinical side, the questions are straightforward. Management expected the third of five Glix-1 dose cohorts in glioblastoma to begin in September, with all three trial sites enrolling and safety described as clean. Confirmation that the third cohort is dosing on schedule would validate the execution story. The newer catalyst is the ovarian cancer angle: preclinical data showed strong synergy with Olaparib, an ovarian arm was added to the planned Phase 2A expansion, and early talks began with several PARP inhibitor developers. Investors should look for any sign those conversations have progressed beyond the introductory stage, since a partnership could ease the funding problem directly. The pending interim futility analysis in the Chemo4MetPanc pancreatic study, clouded by a competitor's approval in that indication, is another binary event slated for later this year.
Sentiment has warmed noticeably, with bullish readings climbing to 73.5% from 47.2% ahead of the prior report, which suggests some holders see value after the collapse. The chart offers less comfort. At $1.12, the stock sits essentially at its post-earnings low of $1.11, far beneath its 200-day moving average of $2.66 and well below the $2.56 floor of the previous quarter's range. Ultimately, this report comes down to a single question: can BioLineRx show that its cash, royalties and partnering prospects are sufficient to reach the 2027 Glix-1 readout without another round of punishing dilution?